Colchicine

Generic Name: Colchicine

Brand Names: Colcrys, Gloperba, Lodoco, Mitigare

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₅NO_₆

CAS Number: 64-86-8

Unique Ingredient Identifier: SML2Y3J35T

Advanced Drug Monograph

Access comprehensive pharmacological analysis, clinical applications, and therapeutic considerations.

Background: Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as Colchicum autumnale, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events. It has also been investigated in other inflammatory and fibrotic conditions.

Indication: Colchicine is indicated for the prophylaxis and treatment of gout flares. It is also indicated in Familial Mediterranean fever (FMF) in children and adults of four years of age and older. It is also indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease.

Some off-label uses of colchicine include the treatment of the manifestations of Behcet's syndrome, pericarditis, and postpericardiotomy syndrome.

Associated Conditions: Behcet's Syndrome, Cardiovascular Mortality, Coronary Revascularization, Familial Mediterranean Fever (FMF ), Gout Flares, Myocardial Infarction, Pericarditis, Postpericardiotomy Syndrome, Stroke

Clinical Trials

Evaluation of a POlypill and Colchicine for Risk Reduction in Patients With Established Atherosclerotic Cardiovascular Disease

Phase 3

Not yet recruiting

Conditions: Atherothrombotic Diseases
Atherosclerotic Cardiovascular Disease (ASCVD)

Interventions: Drug: Cardiovascular Polypill
Drug: Colchicine 0.5 mg
Drug: Colchicine-placebo 0.5 mg
Drug: Usual Care Group

First Posted Date: 2025-04-16

Last Posted Date: 2025-04-16

Lead Sponsor: Hospital do Coracao

Target Recruit Count: 7713

Registration Number: NCT06930885

Colchicine to Reduce Your SympToms and Lower Levels of Inflammation, Zeroing in on Effective CPPD Disease Treatment

Phase 2

Not yet recruiting

Conditions: CPPD - Calcium Pyrophosphate Deposition Disease

Interventions: Drug: Colchicine Pill
Drug: Placebo

First Posted Date: 2025-03-03

Last Posted Date: 2025-03-05

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 150

Registration Number: NCT06855433

EFFICACY OF COLCHICINE IN IMPROVING CLINICAL OUTCOMES IN PATIENTS WITH MILD TO MODERATE COVID-19 PNEUMONIA IN LAHORE: A RANDOMIZED CONTROL TRIAL

Phase 1

Recruiting

Conditions: COVID - 19

Interventions: Drug: Colchicine 0.5 MG Oral Tablet

First Posted Date: 2025-02-26

Last Posted Date: 2025-04-27

Lead Sponsor: Zaeema Kanwal

Target Recruit Count: 66

Registration Number: NCT06847204

Locations: 🇵🇰
General hospital, Lahore, Punjab, Pakistan

Role of Colchicine As Anti-Inflammatory Therapy in HFpEF

Phase 3

Active, not recruiting

Conditions: HFpEF - Heart Failure with Preserved Ejection Fraction

Interventions: Drug: Colchicine Tablets

First Posted Date: 2025-02-20

Last Posted Date: 2025-02-25

Lead Sponsor: Cairo University

Target Recruit Count: 75

Registration Number: NCT06837623

Locations: 🇪🇬
Cairo University - Kasr Al-Ainy, Cairo, Egypt

Using Tumor Models to Determine Treatments

Phase 2

Not yet recruiting

Conditions: Pancreatic Ductal Carcinoma
Advanced Cancer
Epithelial Tumor

Interventions: Drug: Cobimetinib
Drug: Ponatinib
Drug: Brigatinib
Drug: Colchicine
Drug: Selinexor
Drug: Abemaciclib
Drug: Neratinib
Drug: Doxorubicin
Drug: Etoposide
Drug: Ceritinib

First Posted Date: 2025-02-06

Last Posted Date: 2025-02-18

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 25

Registration Number: NCT06813079

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Pilot Trial of Colchicine for Graft Failure in CABG

Phase 4

Not yet recruiting

Conditions: CABG
Colchicine
Graft Failure

Interventions: Drug: Colchicine

First Posted Date: 2025-01-31

Last Posted Date: 2025-02-10

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 100

Registration Number: NCT06802926

Locations: 🇨🇳
Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China

The Effect of Colchicine on the Occurrence of Atrial Fibrillation After Cardiac Surgery

Phase 4

Recruiting

Conditions: Coronary Artery Disease
Atrial Fibrillation
Coronary Artery Bypass Grafting
Colchicine

Interventions: Drug: Colchicine 0.5 MG
Drug: NSAID

First Posted Date: 2025-01-29

Last Posted Date: 2025-04-10

Lead Sponsor: Tomsk Cardiology Research Institute

Target Recruit Count: 140

Registration Number: NCT06798714

Locations: 🇷🇺
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia, Tomsk, Russian Federation

Baricitinib in CPPD - the BAPTIST Study

Phase 2

Not yet recruiting

Conditions: Calcium Pyrophosphate Deposition Disease
Chondrocalcinosis

Interventions: Drug: Baricitinib 4 MG Oral Tablet
Drug: Methylprednisolone (Corticosteroid)
Drug: Colchicine 1 MG Oral Tablet
Drug: Hydroxychloroquine 200 mg
Combination Product: Methotrexate + Folic Acid

First Posted Date: 2025-01-10

Last Posted Date: 2025-01-10

Lead Sponsor: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio

Target Recruit Count: 32

Registration Number: NCT06768294

Locations: 🇮🇹
IRCCS Galeazzi - Sant Ambrogio Hospital, Milan, Italy

Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias

Phase 4

Recruiting

Conditions: Persistent Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Long-standing Persistent Atrial Fibrillation

Interventions: Device: Farapulse Catheter System
Drug: Low-dose Colchicine

First Posted Date: 2025-01-09

Last Posted Date: 2025-05-06

Lead Sponsor: Vivek Reddy

Target Recruit Count: 275

Registration Number: NCT06765356

Locations: 🇺🇸
Trident Medical Center, North Charleston, South Carolina, United States
🇺🇸
The Mount Sinai Hospital, New York, New York, United States

The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL

Phase 3

Recruiting

Conditions: Intracerebral Hemorrhage
Spontaneous Intracerebral Hemorrhage
Supratentorial Intracerebral Haemorrhage
Acute Intracerebral Haemorrhage
Acute Stroke

Interventions: Other: Control (Standard treatment)
Drug: Deferoxamine Mesylate
Drug: Colchicine 0.5 mg

First Posted Date: 2025-01-08

Last Posted Date: 2025-04-10

Lead Sponsor: The George Institute

Target Recruit Count: 2000

Registration Number: NCT06763055

Locations: 🇦🇺
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy